2011 Casefinding List Revised 02/2011
ICD-9-CM Codes Diagnosis (New codes are in Bold)
140.0 – 199.1 Malignant neoplasms – “solid tumors”
199.2
200.0
– 202.98
203.0
– 208.92
Malignant neoplasm associated with transplanted organ
Malignant neoplasms of lymphoid and histiocytic tissue
Multiple myeloma, immunoproliferative neoplasms, and leukemias
209.0 – 209.30 Malignant neuroendocrine neoplasms
209.31
– 209.36
Merkel cell carcinoma of skin and other specified sites
209.40
– 209.69
*Benign carcinoid tumor of specified sites, other and unknown sites
209.7 – 209.79
225.0 – 225.9
227.3
– 227.4
Secondary neuroendocrine tumors; secondary carcinoid tumors
Benign neoplasm of brain and other parts of the CNS
Benign neoplasm of pituitary, craniopharyngeal duct, pineal gland
228.02
228.1
Hemangioma of intracranial structures
Lymphangioma, any site (screen for reportable brain, CNS and endocrine)
229.9
230.0 – 234.9
236.0
237.0
237.5
237.9
238.4
238.6
– 237.1
– 237.72
238.71
238.72
238.73
238.74
238.75
238.76
238.77
238.79
Benign neoplasm of unspecified site (screen for potential 225-227 miscodes)
Carcinoma in situ Exceptions; 233.4 prostatic intraepithelial neoplasia)
Note: 233.1 includes CIN (non-reportable) and adenocarcinoma in situ of
Cervix (REPORTABLE)
Endometrial stromal neoplasia, low grade (8931/1)
Stromal endometriosis (8931/3 per ICD-O-3)
Stromal myosis (endolymphatic) (8931/3 per ICD-O-3)
Stromatosis, endometrial (8931/3 per ICD-O-3)
Neoplasm of uncertain behavior of pituitary gland, craniopharyngeal duct, pineal gland
Neoplasm of uncertain behavior of brain, spinal cord, meninges (NOS, cerebral, spinal), cranial nerve, other CNS site, acoustic neuroma, neurofibromatosis type 2
Polycythemia vera (9950/3)
Solitary plasmacytoma (9731/3)
Extramedullary plasmacytoma (9734/3)
Essential Thrombocythemia (9962/3)
Essential hemorrhagic thrombocythemia
Essential thrombocytosis
Idiopathic (hemorrhagic) thrombocythemia
Primary thrombocytosis
Refractory anemia (RA) (9980/3)
Refractory anemia with ringed sideroblasts (RARS) (9982/3)
Refractory cytopenia with multilineage dysplasia (RCMD) (9985/3)
Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)
Refractory anemia with excess blasts-1 (RAEB-1) (9983/3)
Refractory anemia with excess blasts-2 (RAEB-2) (9983/3)
Myelodysplastic syndrome with 51 deletion (9986/3) - 51 minus syndrome NOS
Chronic myeloproliferative disease (9960/3)
Myelosclerosis with myeloid metaplasia (9961/3)
Refractory cytopenia with multilineage dysplasia (9985/3)
Therapy-related myelodysplastic syndrome (9987/3)
Myelodysplastic syndrome, unspecified (9989/3)
Myelofibrosis with myeloid metaplasia (9961/3)
Agnogenic myeloid metaplasia
Idiopathic myelofibrosis (chronic)
Myelosclerosis with myeloid metaplasia
Primary myelofibrosis
Post-transplant lymphoproliferative disorder (9987/3)
Lymphoproliferative disease (chronic)NOS (9970/1)

2011 Casefinding List Revised 02/2011
ICD-9-CM Codes Diagnosis (New codes are in Bold)
239.6
259.2
273.2
273.3
273.9
277.88
288.3
288.4
– 239.7
Megakaryocytic myelosclerosis (9961/3)
Myloproliferative disease (chronic) J5511 NOS (9906/3)
Panmyelosis (acute) (9931/3)
Neoplasm of unspecified nature of brain, meninges, cranial nerves
Carcinoid syndrome; hormone secretion by carcinoid tumors
Gamma heavy chain disease; Franklin disease (9762/3)
Waldenstrom macroglobulinemia (9761/3)
Unspecified disorder of plasma protein metabolism (screen for potential 273.3 miscodes)
Tumor lysis syndrome – spontaneous; following antineoplastic drug therapy
Hypereosinophilic Syndrome (9964/3)
Hemophagocytic syndrome (9751/3, 9754/3) Reportable inclusion terms: Histiocytic syndromes
Familial Polycythemia (synonym for polycythemia vera)
Acute myelofibrosis (9931/3)
Malignant pleural effusion
Malignant acites
289.6
289.83
511.81
789.51
999.81 Extravasation of vesicant chemotherapy
V07.3
V07.5 – V07.59
Other prophylactic chemotherapy (screen carefully for miscoded malignancies)
Prophylactic use of agents affecting estrogen receptors and estrogen levels
Selective estrogen receptor modulators (SERMs)
Aromatase inhibitors
Other agents affecting estrogen receptors and estrogen levels
V10.0
– V10.91
Personal history of malignancy (review these for recurrences, subsequent primaries and/or subsequent treatment.)
Personal history of benign neoplasm of the brain V12.41
V58.0 Admission for radiotherapy
V58.11 – V58.12 Admission for chemotherapy
V87.41 Personal history of antineoplastic chemotherapy
V87.42
62.3
– 62.42
92.20 – 92.29
92.30 – 92.39
Personal history of monoclonal drug therapy
Orchiectomies (Treatment for prostate malignancies)
Therapeutic radioisotope administration
Stereotactic radiosurgery, NOS
* Carcinoid tumor NOS (8240/3) is reportable for all sites except appendix. Records coded as benign carcinoid tumors should be reviewed to verify that the tumors are actually benign.
Supplementary List
The following table includes ICD-9 codes that CDC-NPCR or others suggest may be included in a reportable list.
MCR does not include these codes in their reportable list. MCR feels that Including these codes will result in significantly more cases to review but few cases that are reportable so should only be screened if time allows.
ICD-9-CM CODES DIAGNOSIS (New codes are in bold)
042 AIDS (review cases for AIDS-related malignancies)
079.4 Human papillomavirus
079.50 – 079.59 Retrovirus (HTLV, types I, II and 2)
210.0
– 229.9
Benign neoplasms, if non-CNS sites (Screen for incorrectly coded malignancies or reportable by agreement tumors)

2011 Casefinding List Revised 02/2011
227.9
235.0
– 236.7,
236.90 – 236.99,
237.2 - 237.4
237.73
238.0 – 239.9
284.9
285.0
285.22
285.3
288.03
289.83
289.9
323.81
379.59
528.01
630
Benign neoplasm of endocrine gland, site unspecified
Neoplasms of uncertain behavior (except for 236.0, which is included in the Reportable list)
(Screen for incorrectly coded malignancies or reportable by agreement tumors)
Schwannomatosis
Neoplasms of uncertain behavior (except for 238.4, 238.6, 238.71-238.79, 239.6, 239.7,
239.81 and 239.89, which are listed in the Reportable list)
(Screen for incorrectly coded malignancies or reportable by agreement tumors)
253.6
Syndrome of inappropriate secretion of antidiuretic hormone
(Note: Part of the paraneoplastic syndrome*)
258.02
– 258.03
Multiple endocrine neoplasia (MEN) type IIA and IIB (rare familial cancer syndrome)
259.8
273.0
Other specified endocrine disorders
Polyclonal hypergammaglobulinemia (Waldenstrom) (Review for miscodes)
273.1
273.8
275.42
Monoclonal gammopathy of undetermined significance (9765/1)
(Screen for incorrectly coded Waldenstrom macroglobulinemia or progression)
Other disorders of plasma protein metabolism
Hypercalcemia (Note: Part of the paraneoplastic syndrome*)
279.00 Hypogammaglobulinemia (Predisposed to lymphoma or stomach cancer)
279.02 – 279.06
Selective IgM immunodeficiency (Associated with lymphoproliferative disorders)
279.10 Immunodeficiency with predominant T-Cell defect, NOS
279.12
279.13
284.81
284.89
Wiskott-Aldrich Syndrome
Nezelof”s Syndrome
Red cell aplasia (acquired, adult, with thymoma)
Other specified aplastic anemias due to drugs (chemotherapy or immunotherapy), infection, radiation
Aplastic anemia, unspecified (Review for miscodes)
Sideroblastic anemia
Anemia in neoplastic disease (neoplasm may be causing anemia)
Antineoplastic chemotherapy induced anemia (Anemia due to antineoplastic chemotherapy)
Drug induced neutropenia
Myelofibrosis (NOS) (9961/3) (some associated with malignancy)
Other specified diseases of blood and blood-forming organs (Review for miscodes)
Encephalomyelitis; specified cause NEC (Note: Part of the paraneoplastic syndrome*)
Opsoclonia (Note: Part of the paraneoplastic syndrome*)
Mucositis due to antineoplastic therapy
Hydatiform Mole (9100/0) a benign tumor that can become malignant, but is then coded as Choriocarcinoma (9100/3) and is coded in the 140-209 range
686.01
695.89
701.2
710.3
710.4
733.10-733.16
758.0
785.6
790.93
795.06
795.16
Pyoderma gangrenosum (Note: Part of the paraneoplastic syndrome*)
Sweet’s syndrome (Note: Part of the paraneoplastic syndrome*)
Acanthosis nigricans (Note: Part of the paraneoplastic syndrome*)
Dermatomyositis (Note: Part of the paraneoplastic syndrome*)
Polymyositis (Note: Part of the paraneoplastic syndrome*)
Pathologic fracture (bones weakened by process, perhaps neoplasm)
Down’s Syndrome (sometimes associated with myeloid leukemia, 9898/3)
Enlargement of lymph nodes
Elevated prostate specific antigen [PSA]
Papanicolaou smear of cervix with cytologic evidence of malignancy
Papanicalaou smear of vagina with cytologic evidence of malignancy
796.76 Papanicolaou smear of anus with cytologic evidence o f malignancy
795.8
795.81
795.82
795.89
999.31
E879.2
E930.7
Abnormal tumor markers; Elevated tumor associated antigens [TAA]; Elevated tumor specific antigens [TSA];
Elevated carcinoembryonic antigen [CEA]
Elevated cancer antigen 125 [CA -125]
Other abnormal tumor markers
Infection due to central venous catheter (porta-cath)
Adverse effect of radiation therapy
Adverse effect of antineoplastic therapy

2011 Casefinding List Revised 02/2011
E933.1
V12.72
V42.81 – V42.82
V51.0
V84.81
V86.0
V86.1
Adverse effect of immunosuppressive drugs
Colonic polyps (history of)
Organ or tissue replaced by transplant; bone marrow transplant; peripheral stem cell transplant
Encounter for breast reconstruction following mastectomy
Genetic susceptibility to multiple endocrine neoplasia [MEN]
Estrogen receptor positive status [ER+}
Estrogen receptor negative status [ER-]
* These diseases are part of the paraneoplastic syndrome* . “Paraneoplastic syndrome* isn’t cancer. It’s a disease or symptom that is the consequence of cancer but is not due to the local presence of cancer cells.
A paraneoplastic syndrome* may be the first s ign of cancer.”